He wāhi rangahau rongonui a Nicotinamide adenine dinucleotide (NAD+) nā ngā kaipūtaiao o te kāinga me tāwāhi. E whakapono ana te nuinga o ngā kaipūtaiao he hononga tata te taumata o te NAD+ ki ngā mate mau tonu e pā ana ki te koroheketanga, pērā i te mate pukupuku, te momona, te toto toto tiketike me te mate huka.
Ko te keratinocyte carcinoma (KC) te pukupuku kino tino kitea i roto i te hunga kiri mā, tae atu ki te basal cell carcinoma (BCC) me te squamous cell carcinoma (cSCC). Nō nā tata nei, i whakaputa ngā kaipūtaiao o Amerika i tētahi tuhinga matapaki i roto i te J DRUGS DERMATOL mō te tāpiri i ngā NAD precursors NMN me NR hei whakaiti i te mōrearea o te mate pukupuku keratinocyte.
E whakaaro ana te kaituhi kua whakamātauhia e Choy B me ētahi atu kaipūtaiao te nicotinamide (NAM), hei matūtake o te NAD+, hei whakaiti i te maha o ngā mate pukupuku keratinocyte. Heoi, ko te nicotinamide mononucleotide (NMN) me te nicotinamide nucleoside (NR), he matūtake hoki mō te hanga NAD+, he tāpiringa whai hua ake pea hei whakaiti i te maha o ngā mate pukupuku keratinocyte.
Mā te whakahaere ā-waha o te NMN me te NR ka taea te whakanui ake i te taumata o te NAD+
I te tau 2018, i whakamātauhia e Sinclair DA me ētahi atu kaipūtaiao, ki te whakaritea ki te NAM, ko te tango ā-waha i te NMN me te NR hei rongoā i te tangata me te kiore ka piki ake te taumata o te NAD+ i roto i te toto me te ate. Nā te mea i pērā ai, he pai ake te hanga a te NMN me te NR i te NAD+.
He haumaru te NMN me te NR, ā, he pai ake te manawanui ki ēnei
Kua whānuitia te whakamahinga o ngā tāpiringa NMN me NR i roto i te tangata me ngā kararehe, ā, kāore anō kia puta he paitini, he pānga kino kino rānei. I roto i tētahi rangahau haumanu i roto i te 25 o ngā wāhine i mua i te paheketanga me te mate huka i mua i te mate, i tangohia e te NMN te tāpiringa NMN i te horopeta o te 250 mg/rā, ā, i kitea ko te NMN i whakanui ake i te aro o te uaua ki te insulin me te kore e puta he pānga kino. I arotahi te rangahau haumanu tuarua ki te pānga o te tāpiringa NMN ki te kaha ā-tinana o ngā kaioma. E toru tekau mā ono ngā kaiuru i whiwhi i te 300 mg/rā (n=12), 600 mg/rā (n=12) 1200 mg/rā rānei (n=12) NMN, ā, kāore anō kia puta he pānga kino, he pānga kino rānei. Ahakoa kāore anō kia whakaaetia e te US Food and Drug Administration (FDA) ēnei kai e rua mō ngā tāpiringa kai, ka taea te hoko ngāwari i ngā tāpiringa NMN me NR ipurangi, ā, kua tīmata te maha o ngā kaihoko ki te tango i a rātou, me ngā horopeta mai i te 500mg ki te 1000mg/rā. Kāore anō kia kitea he pānga kino.
Ki te whakatauritea ki te NAM, ka taea e te NMN me te NR ā-waha te whakanui ake i te taumata NAD+ me te pai ake o te haumaru me te manawanui, he rautaki maimoatanga pea tēnei mā ngā tākuta kiri hei whakaiti i te mōrearea o te mate pukupuku keratinocyte. Heoi anō, me nui tonu ngā raraunga rangahau haumanu hei manatoko i tōna whakamahinga mahi i roto i te maimoatanga haumanu.
Ngā Tohutoro:
[1]. Kahn B, Borrelli M, Libby T. He Arotake Kōrero mō ngā Takawaenga Nicotinamide Adenine Dinucleotide (NAD)+ Nicotinamide Riboside me te Nicotinamide Mononucleotide mō te Whakaiti i te Mōrearea o te Keratinocyte Carcinoma. J Drugs Dermatol. 2022 Oketopa 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.
Wā tuku: Oketopa-25-2022